Companies: 10,795·Total market cap: $144.5T
Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd

HKPDNASDAQHealthcare● Active
$0.48
$-0.01(-2.99%)
Market Cap$5270089
P/E Ratio
52W High$2.58
52W Low$0.37

Cellyan Biotechnology Co., Ltd (HKPD) Revenue

Annual & quarterly revenue history · segment & region breakdown

HKPD · revenue · updated Jun 8, 2026

Core revenue metrics

Cellyan Biotechnology Co., Ltd trailing twelve-month (TTM) revenue is $0.04B, an increase of 21.72% year-over-year from $0.02B in FY2025.

TTM revenue
$0.04B
4-quarter sum · USD
YoY growth
+21.72%
vs FY2025 $0.02B
Price / sales
0.14×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$1370K
27 employees
FY2025
$0.02B
FY2024
$0.02B
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Cellyan Biotechnology Co., Ltd SEC filings · GAAPUpdated: 2026-06-08

Revenue trend

20252023 · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
2025-03-31$0.02B+$0.00B+21.72%
2024-03-31$0.02B+$0.00B+32.91%
2023-03-31$0.01B
HKPD revenue by year · HKPD revenue history · HKPD annual revenue data

Revenue breakdown

Segment & Geography
By business segment
Total$0.01B
$0.01B100.0%
By geography
No segment data available for this period.
Data from Cellyan Biotechnology Co., Ltd annual 10-K filing · FY ending 2025-03-31
HKPD revenue breakdown · HKPD revenue by segment · HKPD revenue by region

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Cellyan Biotechnology Co., Ltd receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Cellyan Biotechnology Co., Ltd reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Cellyan Biotechnology Co., Ltd's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

HKPD revenue · 4 questions

HKPD's trailing twelve-month (TTM) revenue is $0.04B. That is an increase of 21.72% year-over-year from $0.02B in FY2025.

HKPD revenueHKPD annual revenuewhat is HKPD revenueHKPD TTM revenue

Source: FMP · Cellyan Biotechnology Co., Ltd SEC filings · GAAP · Cellyan Biotechnology Co., Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026